以双特异性抗体 XmAb 18968 靶向 CD38 治疗复发/难治性急性髓系白血病和 T 细胞急性淋巴细胞白血病患者 Targeting CD38 with bispecific antibody XmAb 18968 in patients with relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia PubMed 2026/09/14 发表LeukemiaQ1 · IF 8.8(JCR 2025) 人群:成人靶点:CD38靶点:CD7技术:CAR-T技术:双特异性抗体急性淋巴细胞白血病急性髓系白血病
免疫治疗在成人急性白血病治疗中处于何种地位? Where do immunotherapies stand in management of acute leukemia in adults? PubMed 2025/12/05 发表Hematology Am Soc Hematol Educ ProgramQ1 · IF 3.7(JCR 2025) 人群:成人靶点:CD19靶点:CD38靶点:CD7技术:CAR-T急性淋巴细胞白血病急性髓系白血病
战略创新:应对急性髓系白血病免疫治疗的挑战 Strategic innovations: Tackling challenges of immunotherapy in acute myeloid leukemia. PubMed 2025/08/30 发表Chin J Cancer ResQ1 · IF 6.7(JCR 2025) 靶点:CD38靶点:CD70靶点:CD123技术:CAR-T技术:双特异性抗体急性髓系白血病
CAR-T 细胞治疗急性髓系白血病:目前所处的位置 CAR-T Cell Therapy for Acute Myeloid Leukemia: Where Do We Stand Now? PubMed 2025/05/30 发表Curr OncolQ2 · IF 3.6(JCR 2025) 靶点:CD19靶点:CD38靶点:CD123技术:CAR-T急性髓系白血病慢性淋巴细胞白血病